Compare TNXP & LFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | LFMD |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 218.1M |
| IPO Year | 2008 | 2012 |
| Metric | TNXP | LFMD |
|---|---|---|
| Price | $13.32 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.14 |
| AVG Volume (30 Days) | 486.9K | ★ 950.0K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.75 | ★ 141.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | $12,468,578.00 |
| Revenue This Year | $558.11 | $17.52 |
| Revenue Next Year | $38.29 | $18.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 29.85 | ★ 49.79 |
| 52 Week Low | $9.40 | $2.60 |
| 52 Week High | $29.19 | $7.32 |
| Indicator | TNXP | LFMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 36.52 |
| Support Level | $11.98 | $3.00 |
| Resistance Level | $13.36 | $3.41 |
| Average True Range (ATR) | 0.71 | 0.14 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 52.17 | 14.29 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.